S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine whether S-1 increases overall survival
when compared to 5-Fluorouracil (5-FU) in patients with metastatic pancreatic cancer
previously treated with a gemcitabine-based therapy.
The secondary objectives are to compare: progression free survival, overall response rate,
clinical benefit and improvement in tumor related symptoms and also to assess overall safety
and pharmacokinetics of S-1.